HEADER APOPTOSIS 21-JAN-21 7LHB TITLE CRYSTAL STRUCTURE OF BCL-2 IN COMPLEX WITH PRODRUG ABBV-167 COMPND MOL_ID: 1; COMPND 2 MOLECULE: APOPTOSIS REGULATOR BCL-2; COMPND 3 CHAIN: A, B, C; COMPND 4 FRAGMENT: UNP RESIDUES 35-91 REPLACED WITH DVEENRTEAPEGTESE; COMPND 5 ENGINEERED: YES; COMPND 6 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS, SYNTHETIC CONSTRUCT; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606, 32630; SOURCE 5 GENE: BCL2; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI BL21(DE3); SOURCE 7 EXPRESSION_SYSTEM_TAXID: 469008 KEYWDS BCL-2, APOPTOSIS, PRODRUG, ABBV-167 EXPDTA X-RAY DIFFRACTION AUTHOR R.A.JUDGE,A.H.SALEM REVDAT 4 18-OCT-23 7LHB 1 REMARK REVDAT 3 13-APR-22 7LHB 1 COMPND FORMUL REVDAT 2 16-JUN-21 7LHB 1 JRNL REVDAT 1 14-APR-21 7LHB 0 JRNL AUTH A.H.SALEM,Z.F.TAO,O.F.BUENO,J.CHEN,S.CHEN,R.EDALJI, JRNL AUTH 2 S.W.ELMORE,K.M.FOURNIER,K.C.HARPER,R.HONG,G.J.JENKINS,J.JI, JRNL AUTH 3 R.A.JUDGE,J.C.KALVASS,R.C.KLIX,Y.Y.KU,J.D.LEVERSON, JRNL AUTH 4 R.A.MARKS,K.C.MARSH,R.M.MENON,C.H.PARK,D.C.PHILLIPS,Y.M.PU, JRNL AUTH 5 S.H.ROSENBERG,Y.D.SANZGIRI,A.Y.SHEIKH,Y.SHI,D.STOLARIK, JRNL AUTH 6 A.A.SULEIMAN,X.WANG,G.G.Z.ZHANG,N.D.CATRON,A.J.SOUERS JRNL TITL EXPANDING THE REPERTOIRE FOR "LARGE SMALL MOLECULES": JRNL TITL 2 PRODRUG ABBV-167 EFFICIENTLY CONVERTS TO VENETOCLAX WITH JRNL TITL 3 REDUCED FOOD EFFECT IN HEALTHY VOLUNTEERS. JRNL REF MOL.CANCER THER. V. 20 999 2021 JRNL REFN ESSN 1538-8514 JRNL PMID 33785651 JRNL DOI 10.1158/1535-7163.MCT-21-0077 REMARK 2 REMARK 2 RESOLUTION. 2.07 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : BUSTER 2.11.7 REMARK 3 AUTHORS : BRICOGNE,BLANC,BRANDL,FLENSBURG,KELLER, REMARK 3 : PACIOREK,ROVERSI,SHARFF,SMART,VONRHEIN, REMARK 3 : WOMACK,MATTHEWS,TEN EYCK,TRONRUD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.07 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 60.61 REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL REMARK 3 COMPLETENESS FOR RANGE (%) : 99.5 REMARK 3 NUMBER OF REFLECTIONS : 32544 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.204 REMARK 3 R VALUE (WORKING SET) : 0.203 REMARK 3 FREE R VALUE : 0.238 REMARK 3 FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 FREE R VALUE TEST SET COUNT : 1607 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : NULL REMARK 3 BIN RESOLUTION RANGE HIGH (ANGSTROMS) : 2.07 REMARK 3 BIN RESOLUTION RANGE LOW (ANGSTROMS) : 2.08 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 99.68 REMARK 3 REFLECTIONS IN BIN (WORKING + TEST SET) : NULL REMARK 3 BIN R VALUE (WORKING + TEST SET) : NULL REMARK 3 REFLECTIONS IN BIN (WORKING SET) : NULL REMARK 3 BIN R VALUE (WORKING SET) : 0.2689 REMARK 3 BIN FREE R VALUE : 0.3325 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 BIN FREE R VALUE TEST SET COUNT : 38 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 3383 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 201 REMARK 3 SOLVENT ATOMS : 205 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 51.33 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -19.31370 REMARK 3 B22 (A**2) : 9.92660 REMARK 3 B33 (A**2) : 9.38710 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : -11.40270 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.310 REMARK 3 DPI (BLOW EQ-10) BASED ON R VALUE (A) : 0.197 REMARK 3 DPI (BLOW EQ-9) BASED ON FREE R VALUE (A) : 0.167 REMARK 3 DPI (CRUICKSHANK) BASED ON R VALUE (A) : 0.195 REMARK 3 DPI (CRUICKSHANK) BASED ON FREE R VALUE (A) : 0.167 REMARK 3 REMARK 3 REFERENCES: BLOW, D. (2002) ACTA CRYST D58, 792-797 REMARK 3 CRUICKSHANK, D.W.J. (1999) ACTA CRYST D55, 583-601 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.915 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.910 REMARK 3 REMARK 3 NUMBER OF GEOMETRIC FUNCTION TERMS DEFINED : 15 REMARK 3 TERM COUNT WEIGHT FUNCTION. REMARK 3 BOND LENGTHS : 3699 ; 2.000 ; HARMONIC REMARK 3 BOND ANGLES : 5026 ; 2.000 ; HARMONIC REMARK 3 TORSION ANGLES : 1306 ; 2.000 ; SINUSOIDAL REMARK 3 TRIGONAL CARBON PLANES : NULL ; NULL ; NULL REMARK 3 GENERAL PLANES : 737 ; 5.000 ; HARMONIC REMARK 3 ISOTROPIC THERMAL FACTORS : 3699 ; 10.000 ; HARMONIC REMARK 3 BAD NON-BONDED CONTACTS : NULL ; NULL ; NULL REMARK 3 IMPROPER TORSIONS : NULL ; NULL ; NULL REMARK 3 PSEUDOROTATION ANGLES : NULL ; NULL ; NULL REMARK 3 CHIRAL IMPROPER TORSION : 407 ; 5.000 ; SEMIHARMONIC REMARK 3 SUM OF OCCUPANCIES : NULL ; NULL ; NULL REMARK 3 UTILITY DISTANCES : NULL ; NULL ; NULL REMARK 3 UTILITY ANGLES : NULL ; NULL ; NULL REMARK 3 UTILITY TORSION : NULL ; NULL ; NULL REMARK 3 IDEAL-DIST CONTACT TERM : 3137 ; 4.000 ; SEMIHARMONIC REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.008 REMARK 3 BOND ANGLES (DEGREES) : 0.81 REMARK 3 PEPTIDE OMEGA TORSION ANGLES (DEGREES) : 2.98 REMARK 3 OTHER TORSION ANGLES (DEGREES) : 16.71 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 7LHB COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 22-JAN-21. REMARK 100 THE DEPOSITION ID IS D_1000254083. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 09-AUG-10 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 8.0 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : APS REMARK 200 BEAMLINE : 17-ID REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.000 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC QUANTUM 210 REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XDS BUILT 20191015 REMARK 200 DATA SCALING SOFTWARE : XDS REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 32544 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.068 REMARK 200 RESOLUTION RANGE LOW (A) : 60.610 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.5 REMARK 200 DATA REDUNDANCY : 3.400 REMARK 200 R MERGE (I) : 0.05400 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 12.9000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.07 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.10 REMARK 200 COMPLETENESS FOR SHELL (%) : NULL REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: MOLREP REMARK 200 STARTING MODEL: PDB ENTRY 4LVT REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 46.66 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.31 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 20% W/V PEG4000, 0.1 M TRIS-HCL, PH REMARK 280 8.0, 0.2 M CALCIUM CHLORIDE, VAPOR DIFFUSION, HANGING DROP, REMARK 280 TEMPERATURE 277K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 24.72400 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2, 3 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 3 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: C REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 MET A 1 REMARK 465 ALA A 2 REMARK 465 HIS A 3 REMARK 465 PRO A 4 REMARK 465 GLY A 5 REMARK 465 ARG A 6 REMARK 465 THR A 7 REMARK 465 GLY A 8 REMARK 465 ASP A 72 REMARK 465 ALA A 73 REMARK 465 GLY A 74 REMARK 465 ASP A 75 REMARK 465 ASP A 76 REMARK 465 VAL A 77 REMARK 465 GLU A 78 REMARK 465 GLU A 79 REMARK 465 ASN A 80 REMARK 465 ARG A 81 REMARK 465 THR A 82 REMARK 465 GLU A 83 REMARK 465 ALA A 84 REMARK 465 PRO A 85 REMARK 465 GLU A 86 REMARK 465 GLY A 87 REMARK 465 THR A 88 REMARK 465 GLU A 89 REMARK 465 SER A 205 REMARK 465 MET A 206 REMARK 465 ARG A 207 REMARK 465 MET B 1 REMARK 465 ALA B 2 REMARK 465 HIS B 3 REMARK 465 PRO B 4 REMARK 465 GLY B 5 REMARK 465 ARG B 6 REMARK 465 THR B 7 REMARK 465 GLY B 8 REMARK 465 ASP B 72 REMARK 465 ALA B 73 REMARK 465 GLY B 74 REMARK 465 ASP B 75 REMARK 465 ASP B 76 REMARK 465 VAL B 77 REMARK 465 GLU B 78 REMARK 465 GLU B 79 REMARK 465 ASN B 80 REMARK 465 ARG B 81 REMARK 465 THR B 82 REMARK 465 GLU B 83 REMARK 465 ALA B 84 REMARK 465 PRO B 85 REMARK 465 GLU B 86 REMARK 465 GLY B 87 REMARK 465 THR B 88 REMARK 465 GLU B 89 REMARK 465 SER B 90 REMARK 465 SER B 205 REMARK 465 MET B 206 REMARK 465 ARG B 207 REMARK 465 MET C 1 REMARK 465 ALA C 2 REMARK 465 HIS C 3 REMARK 465 PRO C 4 REMARK 465 GLY C 5 REMARK 465 ARG C 6 REMARK 465 THR C 7 REMARK 465 GLY C 8 REMARK 465 TYR C 9 REMARK 465 ASP C 72 REMARK 465 ALA C 73 REMARK 465 GLY C 74 REMARK 465 ASP C 75 REMARK 465 ASP C 76 REMARK 465 VAL C 77 REMARK 465 GLU C 78 REMARK 465 GLU C 79 REMARK 465 ASN C 80 REMARK 465 ARG C 81 REMARK 465 THR C 82 REMARK 465 GLU C 83 REMARK 465 ALA C 84 REMARK 465 PRO C 85 REMARK 465 GLU C 86 REMARK 465 GLY C 87 REMARK 465 THR C 88 REMARK 465 GLU C 89 REMARK 465 SER C 90 REMARK 465 GLU C 91 REMARK 465 VAL C 92 REMARK 465 VAL C 93 REMARK 465 GLY C 203 REMARK 465 PRO C 204 REMARK 465 SER C 205 REMARK 465 MET C 206 REMARK 465 ARG C 207 REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue XZD A 4000 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue XZD B 4000 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue XZD C 4000 DBREF 7LHB A 1 75 UNP P10415 BCL2_HUMAN 1 34 DBREF 7LHB A 76 91 PDB 7LHB 7LHB 76 91 DBREF 7LHB A 92 207 UNP P10415 BCL2_HUMAN 92 207 DBREF 7LHB B 1 75 UNP P10415 BCL2_HUMAN 1 34 DBREF 7LHB B 76 91 PDB 7LHB 7LHB 76 91 DBREF 7LHB B 92 207 UNP P10415 BCL2_HUMAN 92 207 DBREF 7LHB C 1 75 UNP P10415 BCL2_HUMAN 1 34 DBREF 7LHB C 76 91 PDB 7LHB 7LHB 76 91 DBREF 7LHB C 92 207 UNP P10415 BCL2_HUMAN 92 207 SEQADV 7LHB PRO A 4 UNP P10415 ALA 4 ENGINEERED MUTATION SEQADV 7LHB LYS A 26 UNP P10415 ARG 26 ENGINEERED MUTATION SEQADV 7LHB PRO B 4 UNP P10415 ALA 4 ENGINEERED MUTATION SEQADV 7LHB LYS B 26 UNP P10415 ARG 26 ENGINEERED MUTATION SEQADV 7LHB PRO C 4 UNP P10415 ALA 4 ENGINEERED MUTATION SEQADV 7LHB LYS C 26 UNP P10415 ARG 26 ENGINEERED MUTATION SEQRES 1 A 166 MET ALA HIS PRO GLY ARG THR GLY TYR ASP ASN ARG GLU SEQRES 2 A 166 ILE VAL MET LYS TYR ILE HIS TYR LYS LEU SER GLN LYS SEQRES 3 A 166 GLY TYR GLU TRP ASP ALA GLY ASP ASP VAL GLU GLU ASN SEQRES 4 A 166 ARG THR GLU ALA PRO GLU GLY THR GLU SER GLU VAL VAL SEQRES 5 A 166 HIS LEU THR LEU ARG GLN ALA GLY ASP ASP PHE SER ARG SEQRES 6 A 166 ARG TYR ARG ARG ASP PHE ALA GLU MET SER SER GLN LEU SEQRES 7 A 166 HIS LEU THR PRO PHE THR ALA ARG GLY ARG PHE ALA THR SEQRES 8 A 166 VAL VAL GLU GLU LEU PHE ARG ASP GLY VAL ASN TRP GLY SEQRES 9 A 166 ARG ILE VAL ALA PHE PHE GLU PHE GLY GLY VAL MET CYS SEQRES 10 A 166 VAL GLU SER VAL ASN ARG GLU MET SER PRO LEU VAL ASP SEQRES 11 A 166 ASN ILE ALA LEU TRP MET THR GLU TYR LEU ASN ARG HIS SEQRES 12 A 166 LEU HIS THR TRP ILE GLN ASP ASN GLY GLY TRP ASP ALA SEQRES 13 A 166 PHE VAL GLU LEU TYR GLY PRO SER MET ARG SEQRES 1 B 166 MET ALA HIS PRO GLY ARG THR GLY TYR ASP ASN ARG GLU SEQRES 2 B 166 ILE VAL MET LYS TYR ILE HIS TYR LYS LEU SER GLN LYS SEQRES 3 B 166 GLY TYR GLU TRP ASP ALA GLY ASP ASP VAL GLU GLU ASN SEQRES 4 B 166 ARG THR GLU ALA PRO GLU GLY THR GLU SER GLU VAL VAL SEQRES 5 B 166 HIS LEU THR LEU ARG GLN ALA GLY ASP ASP PHE SER ARG SEQRES 6 B 166 ARG TYR ARG ARG ASP PHE ALA GLU MET SER SER GLN LEU SEQRES 7 B 166 HIS LEU THR PRO PHE THR ALA ARG GLY ARG PHE ALA THR SEQRES 8 B 166 VAL VAL GLU GLU LEU PHE ARG ASP GLY VAL ASN TRP GLY SEQRES 9 B 166 ARG ILE VAL ALA PHE PHE GLU PHE GLY GLY VAL MET CYS SEQRES 10 B 166 VAL GLU SER VAL ASN ARG GLU MET SER PRO LEU VAL ASP SEQRES 11 B 166 ASN ILE ALA LEU TRP MET THR GLU TYR LEU ASN ARG HIS SEQRES 12 B 166 LEU HIS THR TRP ILE GLN ASP ASN GLY GLY TRP ASP ALA SEQRES 13 B 166 PHE VAL GLU LEU TYR GLY PRO SER MET ARG SEQRES 1 C 166 MET ALA HIS PRO GLY ARG THR GLY TYR ASP ASN ARG GLU SEQRES 2 C 166 ILE VAL MET LYS TYR ILE HIS TYR LYS LEU SER GLN LYS SEQRES 3 C 166 GLY TYR GLU TRP ASP ALA GLY ASP ASP VAL GLU GLU ASN SEQRES 4 C 166 ARG THR GLU ALA PRO GLU GLY THR GLU SER GLU VAL VAL SEQRES 5 C 166 HIS LEU THR LEU ARG GLN ALA GLY ASP ASP PHE SER ARG SEQRES 6 C 166 ARG TYR ARG ARG ASP PHE ALA GLU MET SER SER GLN LEU SEQRES 7 C 166 HIS LEU THR PRO PHE THR ALA ARG GLY ARG PHE ALA THR SEQRES 8 C 166 VAL VAL GLU GLU LEU PHE ARG ASP GLY VAL ASN TRP GLY SEQRES 9 C 166 ARG ILE VAL ALA PHE PHE GLU PHE GLY GLY VAL MET CYS SEQRES 10 C 166 VAL GLU SER VAL ASN ARG GLU MET SER PRO LEU VAL ASP SEQRES 11 C 166 ASN ILE ALA LEU TRP MET THR GLU TYR LEU ASN ARG HIS SEQRES 12 C 166 LEU HIS THR TRP ILE GLN ASP ASN GLY GLY TRP ASP ALA SEQRES 13 C 166 PHE VAL GLU LEU TYR GLY PRO SER MET ARG HET XZD A4000 67 HET XZD B4000 67 HET XZD C4000 67 HETNAM XZD PHOSPHORIC ACID MONO-[5-(5-{4-[2-(4-CHLORO-PHENYL)-4,4- HETNAM 2 XZD DIMETHYL-CYCLOHEX-1-ENYLMETHYL]-PIPERAZIN-1-YL}-2-{3- HETNAM 3 XZD NITRO-4-[(TETRAHYDRO-PYRAN-4-YLMETHYL)-AMINO]- HETNAM 4 XZD BENZENESULFONYLAMINOCARBONYL}-PHENOXY)-PYRROLO[2,3- HETNAM 5 XZD B]PYRIDIN-7-YLMETHYL] ESTER FORMUL 4 XZD 3(C46 H53 CL N7 O11 P S) FORMUL 7 HOH *205(H2 O) HELIX 1 AA1 ASP A 10 LYS A 26 1 17 HELIX 2 AA2 GLU A 91 TYR A 108 1 18 HELIX 3 AA3 TYR A 108 LEU A 119 1 12 HELIX 4 AA4 THR A 125 ARG A 139 1 15 HELIX 5 AA5 ASN A 143 ARG A 164 1 22 HELIX 6 AA6 PRO A 168 HIS A 184 1 17 HELIX 7 AA7 LEU A 185 ASN A 192 1 8 HELIX 8 AA8 GLY A 193 GLY A 203 1 11 HELIX 9 AA9 ASP B 10 LYS B 26 1 17 HELIX 10 AB1 VAL B 92 TYR B 108 1 17 HELIX 11 AB2 TYR B 108 LEU B 119 1 12 HELIX 12 AB3 THR B 125 PHE B 138 1 14 HELIX 13 AB4 ASN B 143 ARG B 164 1 22 HELIX 14 AB5 PRO B 168 LEU B 185 1 18 HELIX 15 AB6 LEU B 185 ASN B 192 1 8 HELIX 16 AB7 GLY B 193 GLY B 203 1 11 HELIX 17 AB8 ASN C 11 GLN C 25 1 15 HELIX 18 AB9 LEU C 95 TYR C 108 1 14 HELIX 19 AC1 TYR C 108 LEU C 119 1 12 HELIX 20 AC2 THR C 125 ARG C 139 1 15 HELIX 21 AC3 ASN C 143 ARG C 164 1 22 HELIX 22 AC4 PRO C 168 LEU C 185 1 18 HELIX 23 AC5 LEU C 185 ASN C 192 1 8 HELIX 24 AC6 GLY C 193 GLU C 200 1 8 SITE 1 AC1 21 ALA A 100 ASP A 103 ARG A 107 TYR A 108 SITE 2 AC1 21 ASP A 111 PHE A 112 GLU A 136 ASN A 143 SITE 3 AC1 21 TRP A 144 GLY A 145 VAL A 148 ALA A 149 SITE 4 AC1 21 GLU A 152 PHE A 153 VAL A 156 PHE A 198 SITE 5 AC1 21 TYR A 202 HOH A4101 HOH A4115 HOH A4151 SITE 6 AC1 21 ARG B 109 SITE 1 AC2 19 ALA B 100 ASP B 103 PHE B 104 ARG B 107 SITE 2 AC2 19 TYR B 108 GLU B 136 LEU B 137 ASN B 143 SITE 3 AC2 19 TRP B 144 GLY B 145 VAL B 148 ALA B 149 SITE 4 AC2 19 GLU B 152 PHE B 153 PHE B 198 TYR B 202 SITE 5 AC2 19 HOH B4101 HOH B4120 HOH B4153 SITE 1 AC3 19 ALA C 100 ASP C 103 ARG C 107 TYR C 108 SITE 2 AC3 19 ASP C 111 PHE C 112 MET C 115 GLU C 136 SITE 3 AC3 19 LEU C 137 ASN C 143 TRP C 144 GLY C 145 SITE 4 AC3 19 ARG C 146 VAL C 148 ALA C 149 PHE C 198 SITE 5 AC3 19 TYR C 202 HOH C4121 HOH C4125 CRYST1 62.362 49.448 89.359 90.00 103.63 90.00 P 1 21 1 6 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.016035 0.000000 0.003888 0.00000 SCALE2 0.000000 0.020223 0.000000 0.00000 SCALE3 0.000000 0.000000 0.011515 0.00000